Phase 2 Prostate Cancer Trial, Recruiting (NCT06134232)

Phase 2 Prostate Cancer Trial, Recruiting NCT06134232 Sponsor: Dendreon Condition: Prostate Cancer

Printed from Voxsanity (voxsanity.com.au) — NCT06134232 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Prostate Cancer

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

Men aged 18 or older who have prostate cancer that has spread to other parts of the body, is no longer responding to hormone treatment, and causes no symptoms or only mild symptoms.
Men whose doctors have determined they are appropriate candidates for treatment with PROVENGE® (sipuleucel-T) under its approved use.
Men who have already completed all 3 infusions of PROVENGE® before joining the study.
Men who are willing and able to provide written consent to participate before any study procedures begin.
Men with a life expectancy of at least 12 months.

Who may not be able to join:

Men whose prostate cancer does not fit the specific type that PROVENGE® is approved to treat.
Men who need ongoing treatment with medicines that suppress the immune system, including certain biological medicines, steroids, blood products, immune-stimulating injections, vaccines, or other experimental treatments.
Men who have an uncontrolled ongoing illness — such as an active infection (bacterial, viral, or fungal) or a mental health condition — that could make it difficult to follow the study requirements or complete the PROVENGE® treatment course.
Men who are currently taking part in another experimental or investigational treatment study.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 15 July 2026

Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Nadeem Sheikh, PhD, Dendreon Pharmaceuticals, LLC

Phone: 2064588358

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06134232

Sponsor: Dendreon

Phase: Phase 2

Status: Recruiting

Condition: Prostate Cancer

Trial contact: 2064588358

More information: https://clinicaltrials.gov/study/NCT06134232

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

Men aged 18 or older who have prostate cancer that has spread to other parts of the body, is no longer responding to hormone treatment, and causes no symptoms or only mild symptoms.
Men whose doctors have determined they are appropriate candidates for treatment with PROVENGE® (sipuleucel-T) under its approved use.
Men who have already completed all 3 infusions of PROVENGE® before joining the study.
Men who are willing and able to provide written consent to participate before any study procedures begin.
Men with a life expectancy of at least 12 months.

Who may not be able to join:

Men whose prostate cancer does not fit the specific type that PROVENGE® is approved to treat.
Men who need ongoing treatment with medicines that suppress the immune system, including certain biological medicines, steroids, blood products, immune-stimulating injections, vaccines, or other experimental treatments.
Men who have an uncontrolled ongoing illness — such as an active infection (bacterial, viral, or fungal) or a mental health condition — that could make it difficult to follow the study requirements or complete the PROVENGE® treatment course.
Men who are currently taking part in another experimental or investigational treatment study.

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 15 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 2

Sponsor

Dendreon

Registry

ClinicalTrials.gov

Start date

2 October 2023

Est. completion

31 December 2031

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Assess humoral immune response to PAP and PA2024 after booster infusion

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov